Targeted treatments for complex, chronic heart diseases in cats and dogs
Next generation veterinary pain management for daily use
The world’s first veterinary registered PPI for canine gastric ulceration
Diagnostics for Gastric markers that indicate health and wellness
Tackling some of the most debilitating and chronic diseases of aging in companion animals
Targeted treatments for complex, chronic heart diseases in cats and dogs
US product launch Q4 2023
EU launch Q1 2024
Next generation veterinary pain management for daily use
US product launch Q1 2024;
Q2 2024
The world’s first veterinary registered PPI for canine gastric ulceration
US product launch Q1 2023
EU launch Q3 2023
Diagnostics for Gastric markers that indicate health and wellness
US/EU product launch Q2 2023
Tackling some of the most debilitating and chronic diseases of aging in companion animals
Our research and development model is simple but effective.
We identify diseases in companion animals where there are no approved treatments.
We formulate novel solutions with species specific doses and presentations.
Our research team are bridging the gap between bench and bedside by conducting clinical trials that benefit client-owned dogs and cats.
The data collected is then used as clinical data for veterinary patients
We prove the safety and efficacy of our products to FDA and EMA requirements.
Our research and development model is simple but effective.
We identify diseases in companion animals where there are no approved treatments.
We formulate novel solutions with species specific doses and presentations.
Our translational research team are bridging the gap between bench and bedside by conducting clinical trials that benefit client-owned dogs and cats.
The data collected is then used both as clinical data for veterinary patients and preclinical data for human patients.
We prove the safety and efficacy of our products to FDA and EMA requirements.
We harness our extensive animal research to identify synergies in human medicine.
Keep up to date with our latest advancements and news as we continue to develop and commercialise medicines and diagnostics for use in companion animals.
%20CHASE.png)
The goals of this study are to evaluate a newly developed questionnaire to assess pain and clinical signs associated with CM/SM in dogs and to evaluate how well a novel veterinary pain management product might treat the condition.
Dr. Joshua Stern and Victor Rivas of UC Davis to present cutting edge Feline Hypertrophic Cardiomyopathy (HCM) research to distinguished American College of Veterinary Internal Medicine (ACVIM).
Louise Grubb, founder and CEO of companion animal diagnosis and treatment business TriviumVet wins the IMAGE PwC Businesswoman of the Year Award 2023.
